Idrx

Cambridge, United States

Idrx is a clinical-stage biopharmaceutical that develops oncology-based precision therapies to treat cancer.

$120.0M raised

Aug 2024

Series B

Top Investors

Andreessen HorowitzRA Capital ManagementBlackstone GroupCommodore CapitalNextech Invest

19,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has Idrx raised?

Idrx has raised $120.0M in total funding. The most recent round was Series B. The last funding was announced in August 2024.

Who are Idrx's investors?

Idrx's investors include Andreessen Horowitz, RA Capital Management, Blackstone Group, Commodore Capital, Nextech Invest.

Where is Idrx headquartered?

Idrx is headquartered in Cambridge, United States.

What does Idrx do?

Idrx is a clinical-stage biopharmaceutical that develops oncology-based precision therapies to treat cancer.

What stage is Idrx at?

Idrx is at the Series B stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated August 7, 2024.

MLA

"Idrx — Funding & Investors." VCBacked, August 7, 2024, https://www.vcbacked.co/company/idrx. Accessed June 3, 2026.

APA

VCBacked. (2024). Idrx — Funding & Investors. Retrieved June 3, 2026, from https://www.vcbacked.co/company/idrx

Wikipedia (cite web)

{{cite web |title=Idrx — Funding & Investors |url=https://www.vcbacked.co/company/idrx |website=VCBacked |access-date=June 3, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated August 7, 2024.